Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy

AIDS

Volumn 15, Issue 1, 2001, Pages 23-31

  Jouan, Marc ^a   Savès, Marianne ^c   Tubiana, Roland ^a   Carcelain, Guislaine ^a   Cassoux, Nathalie ^a   Aubron Olivier, Camille ^a   Fillet, Anne Marie ^a   Nciri, Maryem ^c   Sénéchal, Brigitte ^a   Chêne, Geneviève ^c   Tural, Christina ^d   Lasry, Stéphane ^b   Autran, Brigitte ^a   Katlama, Christine ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Service d'Anatomie pathologique   (France)

^c INSERM   (France)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; GANCICLOVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS RETINITIS; EYE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL;

EID: 0035808601     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200101050-00006     Document Type: Article

References (41)

1. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated width zidovudine
2. Cytomegalovirus infection in AIDS patients. Patterns of disease, response to therapy and trends in survival
3. Ocular manifestation of acquired immune deficiency syndrome
4. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group: A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS
5. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS
6. Randomized prospective trial of ganciclovir maintenance therapy for cytomegalovirus retinitis
7. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis
8. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS
9. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
10. Plasma CMV DNA, pp65 antigenaemia and low CD4 count remain risk factors for CMV disease in patients receiving HAART
11. Effects of protease inhibitors on the course of CMV retinitis in relation to lymphocyte responses in HIV+ patients
12. Improved outcome of cytomegalovirus retinitis in AIDS patients after introduction of protease inhibitors
13. Cytomegalovirus retinitis in HIV-infected patients with and without highly active antiretroviral therapy
14. Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy
15. Decrease of cytomegalovirus replication in human immunodeficiency virus infected patients after treatment with highly active antiretroviral therapy
16. Clearance of cytomegalovirus viraemia after initiation of highy active antiretroviral therapy
17. Positive effects of combined antiretroviral therapy on CD4 + T cell homostasis and function in advanced HIV disease
18. Long-lasting recovery in CD4 T-4 cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
19. Restoration of cytomegalovirus-specific CD4 T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
20. Correlation between CD4 counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome
21. Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir
22. Related a oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant
23. Changes in CD4 cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment
24. Cytomegalovirus retinitis after the initiation of highly active antiretroviral therapy: A 2 year prospective study
25. Immune recovery vitritis associated with inactive CMV retinitis a new syndrome
26. Cystoïd macular oedema and cytomegalovirus retinitis in patients with HIV disease treated with highly active antiretroviral therapy
27. Significance of cytomegalovirus pp 65 antigenaemia in the diagnosis of CMV disease in human immunodeficiency virus infected patients
28. High level of quantitative pp 65 cytomegalovirus antigenaemia assay for diagnosis of CMV disease in AIDS patients and follow-up
29. Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy
30. Negative result of cytomegalovirus blood culture with restoration of CD4 T-cell reactivity to cytomegalovirus after HAART in an HIV-1-infected patient
31. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infected adults treated with combination antiretroviral therapy
32. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1 infected patients treated with highly active antiretroviral therapy
33. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral theray in HIV-1 infection
34. Discontinuation of prophylaxis against Mycobacterium avium complet disease in HIV-infected patients who have a response to antiretroviral therapy
35. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients
36. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevation in CD4 T cells in response to highly active antiretroviral therapy
37. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4 counts
38. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis
39. Highly active antiretroviral therapy-related immune recovery in AIDS patients with cytomegalovirus retinitis
40. 1999 USPHS/IDSA guideline for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
41. Prise en charge thérapeutique des personnes infectées par le VIH: Rapport 1999